Investigating the therapeutic potential of venom-derived compounds for the management of Alzheimer's disease: a comprehensive review

Aimen; Muhammad H. Gul; Rohab Sohail; Ritesh Pahwani; Aisha R. Siddiqui; Saffa Nadeem; Abdul B. Wardak; Hamza Nazir; Sarah Ahmad; Aftab Ahmed

doi:10.18203/issn.2454-2156.IntJSciRep20242372

Authors

Aimen Department of Medicine, Bahawal Victoria Hospital, Pakistan https://orcid.org/0009-0007-1326-0847
Muhammad H. Gul Department of Medicine, Lady Reading Hospital, Peshawar, Pakistan https://orcid.org/0009-0007-4044-9207
Rohab Sohail Department of Medicine, Quaid-Azam Medical College Bahawalpur, Pakistan https://orcid.org/0009-0008-8526-4502
Ritesh Pahwani Department of Medicine, Jinnah Sindh Medical University Karachi, Pakistan https://orcid.org/0009-0008-5280-6192
Aisha R. Siddiqui Department of Medicine, Liaquat University of Medical and Health Sciences, Jamshoro, Sindh, Pakistan https://orcid.org/0009-0005-3145-5272
Saffa Nadeem Department of Medicine, Multan Institute of Cardiology, Pakistan https://orcid.org/0009-0006-4675-2218
Abdul B. Wardak Department of Medicine, Razia Bahlol Hospital, Afghanistan https://orcid.org/0000-0002-9929-6088
Hamza Nazir Department of Medicine, Hayatabad Medical Complex, Pakistan https://orcid.org/0009-0008-8023-4400
Sarah Ahmad Department of Medicine, Khyber Medical College, Peshawar, Pakistan https://orcid.org/0009-0008-4707-0600
Aftab Ahmed Department of Medicine, Cork University Hospital, Cork, Ireland https://orcid.org/0009-0009-0684-6676

DOI:

https://doi.org/10.18203/issn.2454-2156.IntJSciRep20242372

Keywords:

Alzheimer’s disease, Pharmacological treatment, Bee venoms, Venom-derived substances, Therapeutic effects

Abstract

Alzheimer’s disease is a comprehensive clinical syndrome featuring cognitive, emotional, and volitional function deterioration. Treatment strategies for Alzheimer's disease involve a mix of pharmacological and non-pharmacological approaches. Current treatments focus on palliative care with limited impact on the disease course. Venom-derived substances, known for their neuroactive properties, have emerged as a novel approach to Alzheimer's treatment. Our team conducted a thorough search for electronic literature related to therapeutic venom-derived substances efficacy in Alzheimer’s disease in different databases, including Medline, PubMed, Google Scholar, and Psych INFO, up to May 2024. In this article, the therapeutic effects of various venom-derived substances effects in Alzheimer’s disease are discussed. Various substances grant anti-inflammatory and anti-oxidant effects. The clinical application of venom-derived therapy is still a long way ahead, still, researchers believe that the ongoing work will eventually allow its compounds to be considered definitive candidates in various therapies in upcoming years.

Metrics

Metrics Loading ...

References

Gustafson L. What is dementia? Acta Neurologica Scandinavica. 1996;94:22-4.

Soria Lopez JA, González HM, Léger GC. Alzheimer’s disease. Handb Clin Neurol. 2019;167:231-55.

Qiu C, Kivipelto M, Von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11(2):111-28.

Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. Global prevalence of dementia: a Delphi consensus study. The Lancet. 2005;366(9503):2112-7.

Buccellato FR, D’Anca M, Tartaglia GM, Del Fabbro M, Scarpini E, Galimberti D. Treatment of Alzheimer’s disease: beyond symptomatic therapies. Int J Mol Sci. 2023;24(18):13900.

Futai E, Kawasaki H, Sato S, Daoudi K, Hidaka M, Tomita T, et al. A Metalloproteinase Cocktail from the Venom of Protobothrops flavoviridis Cleaves Amyloid Beta Peptides at the α-Cleavage Site. Toxins. 2023;15(8):500.

Jeong YA, Yun HS, Kim Y, Jang CH, Lim JS, Kim HJ, et al. Long-Term Administration of Vespa velutina nigrithorax Venom Ameliorates Alzheimer’s Phenotypes in 5xFAD Transgenic Mice. Toxins. 2023;15(3):203.

Li Q, Che HX, Wang CC, Zhang LY, Ding L, Xue CH, et al. Cerebrosides from Sea Cucumber Improved Aβ1–42‐Induced Cognitive Deficiency in a Rat Model of Alzheimer's Disease. Mol Nutr Food Res. 2019;63(5):1800707.

Frangieh J, Salma Y, Haddad K, Mattei C, Legros C, Fajloun Z, et al. First characterization of the venom from apis mellifera syriaca, a honeybee from the middle east region. Toxins. 2019;11(4):191.

Wehbe R, Frangieh J, Rima M, El Obeid D, Sabatier JM, Fajloun Z. Bee venom: Overview of main compounds and bioactivities for therapeutic interests. Molecules. 2019;24(16):2997.

Sachkova MY, Landau M, Surm JM, Macrander J, Singer SA, Reitzel AM, et al. Toxin-like neuropeptides in the sea anemone Nematostella unravel recruitment from the nervous system to venom. Proceed Nat Acad Sci. 2020;117(44):27481-92.

Kumar A, Sidhu J, Goyal A. Alzheimer Disease. StatPearls. Treasure Island (FL): StatPearls Publishing. 2023.

Tang Y, Lutz MW, Xing Y. A systems-based model of Alzheimer's disease. Alzheimers Dement. 2019;15(1):168-71.

Zilberzwige‐Tal S, Gazit E. Go with the flow—Microfluidics approaches for amyloid research. Chemistry. 2018;13(22):3437-47.

Wattmo C, Minthon L, Wallin ÅK. Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy. Alzheimers Res Therapy. 2016;8:1-5.

Breijyeh Z, Karaman R. Comprehensive review on Alzheimer’s disease: causes and treatment. Molecules. 2020;25(24):5789.

Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12(3):292-323.

Apostolova LG. Alzheimer disease. Continuum: Lifelong Learning in Neurology. 2016;22(2):419-34.

Ogawa T, Tobishima Y, Kamata S, Matsuda Y, Muramoto K, Hidaka M, et al. Focused proteomics analysis of habu snake (Protobothrops flavoviridis) venom using antivenom-based affinity chromatography reveals novel myonecrosis-enhancing activity of thrombin-like serine proteases. Front Pharmacol. 2021;12:766406.

Oliveira AL, Viegas MF, da Silva SL, Soares AM, Ramos MJ, Fernandes PA. The chemistry of snake venom and its medicinal potential. Nat Rev Chem. 2022;6(7):451-69.

Tajti G, Wai DC, Panyi G, Norton RS. The voltage-gated potassium channel KV1. 3 as a therapeutic target for venom-derived peptides. Biochem Pharmacol. 2020;181:114146.

Park JS, Kam TI, Lee S, Park H, Oh Y, Kwon SH, et al. Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease. Acta Neuropathologica Comm. 2021;9(1):78.

Kim KH, Lee SY, Shin J, Hwang JT, Jeon HN, Bae H. Dose-dependent neuroprotective effect of standardized bee venom phospholipase A2 against MPTP-induced Parkinson’s disease in mice. Front Aging Neurosci. 2019;11:80.

Chae JH, Oh J, Lim JS, Jeong YA, Yun HS, Jang CH, et al. Wasp Venom Ameliorates Scopolamine-Induced Learning and Memory Impairment in Mice. Toxins. 2022;14(4):256.

Dehghani H, Rashedinia M, Mohebbi G, Vazirizadeh A, Baghban N. Antioxidant and anticholinesterase properties of Echinometra mathaei and Ophiocoma erinaceus venoms from the Persian Gulf. Front Chem. 2024;11:1332921.

Tangrodchanapong T, Sornkaew N, Yurasakpong L, Niamnont N, Nantasenamat C, Sobhon P, et al. Beneficial effects of cyclic ether 2-butoxytetrahydrofuran from sea cucumber Holothuria scabra against Aβ aggregate toxicity in transgenic Caenorhabditis elegans and potential chemical interaction. Molecules. 2021;26(8):2195.